A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

This trial compares a new drug called SKB264 (an antibody-drug combination that targets a protein called TROP2) against standard chemotherapy options for people with triple-negative breast cancer (TNBC) that has spread or cannot be surgically removed. **You may be eligible if...** - You have been diagnosed with triple-negative breast cancer (a type that lacks certain hormone receptors) - Your cancer has either spread from the start or returned at least 6 months after completing treatment aimed at a cure - You have not yet received systemic (whole-body) treatment for metastatic or unresectable disease - Your cancer is PD-L1 negative, OR it is PD-L1 positive but returned after immunotherapy for earlier-stage disease - You are in good physical condition (ECOG 0-1) - You have a life expectancy of at least 3 months - You have adequate organ function **You may NOT be eligible if...** - You have another active cancer - You have significant heart disease - You have a history of severe lung inflammation - You have active hepatitis B, C, or HIV - You have previously received TROP2-targeted therapies or topoisomerase 1 inhibitors - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.